Instinet Incorporated, a global leader in electronic trading and agency-only brokerage services, today announced that its Instinet, LLC subsidiary has entered into an exclusive agreement with Favus Institutional Research, LLC, an independent research provider (IRP) that focuses on the healthcare sector. Under the terms of the agreement, Instinet will provide exclusive sales and marketing services for Favus.

Favus uses fundamental analysis to evaluate the sector, with a focus on commercial, clinical, legal, reimbursement and regulatory catalysts. Favus brings a successful forecast record, including the accuracy of its sell recommendations. As an independent research provider with no investment banking arm, Favus’s sole mission is to produce meaningful research for clients. Favus research is produced by Elliot Favus, M.D., a board-certified internist and former Och-Ziff and Lazard research analyst.

“We’re excited to expand our Access program with the addition of yet another high-quality IRP,” said Jonathan Kellner, President of the Americas at Instinet. “Favus delivers a unique offering in the healthcare research space that will enhance our ability to help our clients in the alpha generation process.”

“Instinet’s sophisticated trading platform and agency-only model make it a natural partner for us,” added Dr. Favus. “I am eager to combine our research product with Instinet's sales and trading capabilities.”

Favus Institutional Research becomes the seventh IRP in the Instinet Access program, which supports high-quality research providers with sales and marketing, account coverage, payment facilitation and other services across Instinet’s institutional client base and beyond.

About Favus Institutional Research, LLC

Favus Institutional Research is an independent healthcare equity research provider. The firm provides institutional investors with valuable healthcare research and divergent information, helping clients better assess healthcare stocks by analyzing information that is not ordinarily available from other research providers. Favus uses fundamental analysis to evaluate the healthcare sector, with a focus on commercial, clinical, legal, reimbursement and regulatory catalysts. The firm is headed by Elliot Favus, M.D., who has equity research and institutional investment management experience at Lazard Capital Markets and Och-Ziff Capital Management Group.

If you liked this article you might like

Stock Picks to Take Advantage of the World's Most-Attractive Emerging Markets

These Property Stocks Are Outperforming, as Hang Seng and Real Estate Both Crest to Highs

A Profitable Play on Southeast Asia's Convenience Stores

Ex-Nomura Trading Chief 'Lied' to Customers About Bond Prices, SEC Says

China Takes a Bite Out of Apple; Foreign Tech Companies Fret